# OnCo record therascreen-cdx (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/therascreen-cdx/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "therascreen-cdx" ;
  schema:name "therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)"@en ;
  schema:description "A family of quick single-gene tests that decide who can have several bowel, lung, breast and bladder cancer drugs."@en ;
  schema:url <https://onco.cc/drugs/therascreen-cdx/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110030>, <https://www.qiagen.com/us/product-categories/diagnostics-and-clinical-research/oncology> ;
  onco:status "approved" ;
  onco:tag "test" ;
  onco:modality "Real-time PCR companion diagnostic test family" ;
  schema:alternateName "therascreen" ;
  onco:approval "US 2012: therascreen KRAS: cetuximab and panitumumab eligibility in metastatic colorectal cancer", "US 2013: therascreen EGFR: afatinib in EGFR-mutant NSCLC", "US 2019: therascreen PIK3CA (tissue and plasma): alpelisib in breast cancer; therascreen FGFR: erdafitinib in urothelial cancer", "US 2020: therascreen BRAF V600E: encorafenib plus cetuximab in colorectal cancer" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/urothelial/> ;
  onco:technologies <https://onco.cc/technologies/companion-diagnostic/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/fgfr2/>, <https://onco.cc/targets/braf/> ;
  onco:drugs <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/afatinib/>, <https://onco.cc/drugs/alpelisib/>, <https://onco.cc/drugs/erdafitinib/>, <https://onco.cc/drugs/encorafenib/> ;
  onco:companies <https://onco.cc/companies/qiagen/> ;
  onco:terms <https://onco.cc/terms/companion-diagnostic-term/> ;
  onco:trials <https://onco.cc/trials/nct07617805/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-karapetis-kras-cetuximab-colorectal-nejm-2008/>, <https://onco.cc/key-papers/paper-douillard-prime-panitumumab-ras-nejm-2013/> .